best of all, gilead, i'm calling this one immune to the fiscal cliff-induced recession. people do not stop taking life-saving medicines just because the economy slows down. alexeon, on the other hand, no. not so hot. the stock has tripled since i first got behind it it's down about 14% since i highlighted it as an anointed growth stock two months ago. that's unacceptable. alexeon is a orphan drug maker whose lead drug has been incredibly successful. however, even though alxn raised guidance, not unlike tractor supply, the stock sold off because the sales only met expectations rather than beating them given the huge run in the stock going to the quarter. alxn had to do more than just meet the expectations. they had to beat that and crush them. and this time around, it got crushed. that said, to me the market overreacted. alexia has received fda approval to use solera for new indication that could be worth $900 million in peak sales and another $2.5 billion worth of new indications that the company is working on just for this one medication. plus they have intriguing thing